AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05879042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Stretching
Description: For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.
Study NCT05879042 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stretching
Description: Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
Study NCT05398315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Statements/Reflections
Description: Presence of Empathic Statements
Study NCT05398315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrator Backstory
Description: Presence of a narrator backstory
Study NCT05398315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Narrator
Description: Presence of a male narrator
Study NCT05398315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Female Narrator
Description: Presence of a female narrator
Study NCT05398315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI Techniques
Description: Presence of MI techniques
Study NCT05679635 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Evone
Description: The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
Study NCT05679635 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Evita Infinity V500
Description: Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
Study NCT05204966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AI analysis
Description: 1. Bottle feeding filming~   - With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input.
Study NCT05980442 — intervention group
Intervention type: DEVICE
Intervention: Navigated total knee arthroplasty
Description: Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
Study NCT05980442 — intervention group
Intervention type: DEVICE
Intervention: Robot assisted total knee arthroplasty
Description: Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
Study NCT05485948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
Study NCT06475144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online escape room teaching
Description: here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.
Study NCT06475144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: online video-based teaching
Description: The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay.
Study NCT05564169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment per os
Study NCT05564169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (4.5)
Description: Masitinib (titration to 4.5 mg/kg/day)
Study NCT05564169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
Study NCT05564169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
Study NCT05337332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Suprachoroidal injection of triamcinolone acetonide
Study NCT05848154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA detection
Description: Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
Study NCT06434480 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: * For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given.
Study NCT05009719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic Donor lymphocytes infusions
Description: Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg.
Study NCT05009719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Preventive Donor lymphocytes infusions
Description: Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg.
Study NCT05098041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets.
Study NCT05098041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules.
Study NCT03530410 — intervention group
Intervention type: DEVICE
Intervention: Intragastric balloon placement
Description: Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
Study NCT05102643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine
Description: A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
Study NCT05102643 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Solution for intramuscular injection
Study NCT04904289 — intervention group
Intervention type: OTHER
Intervention: All intervention of real world
Description: We analyzed all data we can obtain from our databases
Study NCT05335408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acunex Vario intraocular lens
Description: This is an extended depth of focus IOL, made by Teleon Surgical B.V.
Study NCT05335408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon AcrySof IQ Vivity intraocular lens
Description: This is an extended depth of focus IOL, made by Alcon.
Study NCT06212245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab 300 mg
Study NCT04754100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agenT-797
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study NCT05882955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes consumption
Description: Participants will eat one or two recipes a day for 17 weeks
Study NCT05882955 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Recipes consumption
Description: Participants will eat one or two recipes a day for 17 weeks
Study NCT05882955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
Study NCT05882955 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
Study NCT04714541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
Study NCT05060588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 49/51mg/Tab
Description: patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
Study NCT05060588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80mg/Tab
Description: Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
Study NCT06549569 — intervention group
Intervention type: PROCEDURE
Intervention: TFS
Description: burn coverage with TFS
Study NCT06008990 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine
Description: Pregnant mother must be taking Buprenorphine
Study NCT06008990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal Brain MRI
Description: Maternal Brain MRI obtained between 24-32 week gestation
Study NCT06008990 — intervention group
Intervention type: OTHER
Intervention: Blood Samples
Description: During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
Study NCT06008990 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires about their medical history, pregnancy, and substance use.
Study NCT04937556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic: Lactobacillus salivarius + Vit D + Zinc
Description: A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
Study NCT04937556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 1 capsule will be daily administrated during 28 days.
Study NCT06057779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Slow and heavy exercise therapy
Description: 6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
Study NCT06057779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Slow and light exercise therapy
Description: 6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
Study NCT06057779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fast and heavy exercise therapy
Description: 6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
Study NCT05320900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest auscultation
Description: Chest auscultation data
Study NCT05211479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study.
Study NCT05574205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
Study NCT05574205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
Study NCT05501353 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
Study NCT04930055 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccination
Description: Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Study NCT04732182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightGo cognitive training
Description: Training on the BrightGo experimental device in the home
Study NCT04732182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care medication for early Alzheimer's Disease
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
Study NCT04732182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care medication for early Alzheimer's Disease
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
Study NCT05747911 — intervention group
Intervention type: OTHER
Description: Groups will not be intervened. Only observational data will be used.
Study NCT04702165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung resection with Lung Resection Marker Locator Kit
Description: Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
Study NCT05586490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
Study NCT05586490 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
Study NCT05586490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional RehabilitationDevice (MRD)
Description: Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
Study NCT05586490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: existing standard rehabilitation device
Description: existing standard rehabilitation device to be used for in-home comparison testing for aim 3
Study NCT04839367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: 64Cu-SAR-bisPSMA
Study NCT04949698 — intervention group
Intervention type: DEVICE
Intervention: plasma exchange
Description: Plasma exchange was performed daily for five times or until platelet level returned to normal
Study NCT04980612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Pain Reduction
Description: 40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
Study NCT06264024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal collagen cross linking (CXL)
Description: Use of Avedro Inc. KXL 1 system to stop progression of keratoconus
Study NCT06264024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross linking (CXL)
Description: Use of Avedro Inc. KXL 1 system to stop progression of keratoconus
Study NCT06264024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial phototherapeutic keratectomy (t-PTK)
Description: Use Alcon Wavelight 500, excimer laser to remove the epithelium and some of the stroma over apex
Study NCT04980612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: 10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
Study NCT04900597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elecare Jr
Description: Elecare Jr is a standard pediatric elemental formula
Study NCT04900597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nourish
Description: Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
Study NCT04900597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Foods Blends
Description: Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
Study NCT05279846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: Applied topically for 48 weeks
Study NCT05279846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo Comparator)
Description: Applied topically for 48 weeks
Study NCT04847973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-Tailored Meals (MTMs)
Description: 12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
Study NCT04847973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation shakes
Description: 12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
Study NCT05181527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors
Description: Patients in both the study arms will receive SSRI for 8 weeks.
Study NCT05181527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors
Description: Patients in both the study arms will receive SSRI for 8 weeks.
Study NCT05181527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
Study NCT05181527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.